The 6 references without contexts in paper E. Egorenkov A., V. Smirnov V., V. Kuzina N., S. Dementiev P., G. Ramenskaya V., Е. Егоренков А., В. Смирнов В., В. Кузина Н., С. Дементьев П., Г. Раменская В. (2018) “Методики фенотипирования изофермента CYP3A4, применяемые для персонализации фармакотерапии // CYP3A4 isoenzyme phenotyping for personalisation of pharmacotherapy” / spz:neicon:vedomostincesmp:y:2017:i:1:p:20-24

5
Qui H, Mathas M, Nestler S, Bengel C, Nem D, Godtel-Armbrust U, et al. The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability. Pharmacogenetics and Genomics 2010; 20(3): 167–78.
(check this in PDF content)
7
Ainslie GR, Wolf KK, Li Y, Wolf KK, Li Y, Connolly EA, Scarlett YV, Hull JH, Paine MF. Assessment of a candidate marker constituent predictive of a dietary substance-drug interaction: case study with grapefruit juice and CYP3A4 drug substrates. The Journal of Pharmacology and Experimental Therapeutics 2014; 351(3): 576–84.
(check this in PDF content)
8
Kesel PM, Lambert WE, Stove CP. Alternative Sampling Strategies for Cytochrome P450 Phenotyping. Clin Pharmacokinet. 2016; 55(2): 169–84.
(check this in PDF content)
13
Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, et al. Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the «Coopers-town5+1cocktail». Journal of Clinical Pharmacy and Therapeutics 2003; 74: 437–47.
(check this in PDF content)
15
Zgheib NK, Frye RF, Tracy TS, Romkes M, Branch RA. Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Journal of Clinical Pharmacy and Therapeutics 2006; 80: 257–63.
(check this in PDF content)
16
Ryu JY, Song IS, Sunwoo YE, Shon JH, Liu KH, Cha IJ, et al. Development of the «Inje cocktail» for high-throughput evaluation of five human cytochrome P450 isoformsin vivo. Journal of Clinical Pharmacy and Therapeutics 2007; 82: 531–40.
(check this in PDF content)